Assurans 10mg Injection

Assurans 10mg Injection

Assurans 10mg Injection is a high-potency pharmacological intervention containing Sildenafil (10mg/12.5ml), a selective phosphodiesterase type 5 (PDE5) inhibitor specifically engineered for the clinical management of Pulmonary Arterial Hypertension (PAH) (WHO Group I). Utilizing a specialized intravenous delivery system, this medication works by inhibiting the PDE5 enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the pulmonary vasculature. By modulating the nitric oxide-cGMP pathway and promoting sustained vasodilation of the pulmonary bed, Assurans effectively neutralizes the physiological triggers of elevated pulmonary vascular resistance. This targeted biochemical action provides a decisive therapeutic response by improving exercise capacity and delaying clinical worsening in patients who are temporarily unable to take oral medication.

Key Features

• Specifically formulated to target the vascular smooth muscle of the lungs to reduce arterial pressure.
• Clinically recognized for providing a direct therapeutic route for patients with compromised gastrointestinal absorption or acute clinical needs.
• Specifically engineered to increase the concentration of cGMP, facilitating significant improvements in pulmonary blood flow.
• Acts as a functional catalyst to decrease the workload on the right ventricle, enhancing overall cardiac output.
• Formulated to provide immediate therapeutic plasma levels for precise control over pulmonary vascular resistance.

Key Ingredients

• Sildenafil Citrate (10mg)
• Sodium Citrate
• Citric Acid Monohydrate
• Water for Injection

Precautions

• Administration must be performed by a healthcare professional in a clinical setting with continuous monitoring of blood pressure and oxygen saturation.
• Strictly avoid concurrent use with any form of organic nitrates or nitric oxide donors, as this can lead to severe, life-threatening hypotension.
• Use with extreme caution in patients with left ventricular outflow obstruction, resting hypotension, or fluid depletion.
• Inform your physician if you are taking alpha-blockers, protease inhibitors, or other antihypertensive agents to prevent additive hypotensive effects.
• Not recommended for patients with pulmonary veno-occlusive disease (PVOD), as vasodilators may significantly worsen the clinical status.
• Discontinue use immediately if sudden loss of vision or hearing occurs, as these are rare but serious associated risks.

How to Use

• For intravenous bolus injection only. Must be administered by a qualified healthcare professional.
• The standard dose is 10mg (12.5ml) administered three times daily. This intravenous dose is designed to provide exposure equivalent to a 20mg oral dose.
• Ensure the solution is clear and free from particulate matter before administration. The injection should be delivered according to established clinical protocols for PAH management.
• This injectable format is typically used as a short-term replacement for patients who are stabilized on oral Assurans but are temporarily unable to ingest tablets.
• Maintain the prescribed intervals to ensure steady-state concentrations in the pulmonary vasculature.
• Store at controlled room temperature (below 30°C). Do not freeze. Protect the vial from light and keep it in the original carton until the time of use.

Legal Disclaimer: Assurans 10mg Injection is a prescription-only medication for clinical use. Individual results vary based on the severity of pulmonary hypertension and the patient’s overall hemodynamic profile. This product is not intended for the treatment of neonatal pulmonary hypertension. This information is for educational purposes and is not a substitute for professional medical consultation or a formal cardiological assessment.